10
participating drug manufacturers
The Health Resources and Services Administration (HRSA) has selected 10 drug manufacturers and 21 drugs to participate in its revised 340B Rebate Model Pilot Program.
02 Oct — due 01 Jan 2027
Every figure reported in pharma news this week, with what each figure measures, when it was reported and where it was published.
110 figures were reported across 44 pharma articles in this window. The table lists the 60 carried by the highest-ranked articles.
The Health Resources and Services Administration (HRSA) has selected 10 drug manufacturers and 21 drugs to participate in its revised 340B Rebate Model Pilot Program.
02 Oct — due 01 Jan 2027
The Health Resources and Services Administration (HRSA) has selected 10 drug manufacturers and 21 drugs to participate in its revised 340B Rebate Model Pilot Program.
02 Oct — due 01 Jan 2027
The Health Resources and Services Administration (HRSA) has selected 10 drug manufacturers and 21 drugs to participate in its revised 340B Rebate Model Pilot Program.
02 Oct — due 01 Jan 2027
AstraZeneca has entered into a $2 billion deal with Summit Therapeutics to secure rights to the drug candidate ivonescimab, also referred to as Datroway.
29 Sep (reported 02 Oct)
The Centers for Medicare & Medicaid Services (CMS) has finalized the Global Benchmark for Efficient Drug Pricing (GLOBE) model to implement most-favored nation pricing for Medicare Part B. The program is scheduled to begin on January 1, 2027, and will run through March 31, 2032, covering approximately 25% of traditional Medicare beneficiaries. CMS Administrator Mehmet Oz stated the model aims to lower drug costs by benchmarking U.S. prices against those in economically similar countries.
01 Oct — due 01 Jan 2027
Revolution Medicines received FDA approval in late August 2026 for Rasonque (daraxonrasib), the first RAS(ON) inhibitor for metastatic pancreatic ductal adenocarcinoma.
31 Aug (reported 30 Sep)
Revolution Medicines received FDA approval in late August 2026 for Rasonque (daraxonrasib), the first RAS(ON) inhibitor for metastatic pancreatic ductal adenocarcinoma.
31 Aug (reported 30 Sep)
Revolution Medicines received FDA approval in late August 2026 for Rasonque (daraxonrasib), the first RAS(ON) inhibitor for metastatic pancreatic ductal adenocarcinoma.
31 Aug (reported 30 Sep)
Revolution Medicines received FDA approval in late August 2026 for Rasonque (daraxonrasib), the first RAS(ON) inhibitor for metastatic pancreatic ductal adenocarcinoma.
31 Aug (reported 30 Sep)
Citi downgraded Moderna stock from Neutral to Sell on September 30, 2026, citing an unsustainable valuation despite the company's recent 703% share price increase.
30 Sep
Citi downgraded Moderna stock from Neutral to Sell on September 30, 2026, citing an unsustainable valuation despite the company's recent 703% share price increase.
30 Sep
Citi downgraded Moderna stock from Neutral to Sell on September 30, 2026, citing an unsustainable valuation despite the company's recent 703% share price increase.
30 Sep
Citi downgraded Moderna stock from Neutral to Sell on September 30, 2026, citing an unsustainable valuation despite the company's recent 703% share price increase.
30 Sep
Eli Lilly CEO Dave Ricks announced at a conference in Milan that the company plans to pursue larger acquisitions to target underserved medical areas, including infectious diseases, women's health, and psychiatric conditions.
29 Sep
Eli Lilly CEO Dave Ricks announced at a conference in Milan that the company plans to pursue larger acquisitions to target underserved medical areas, including infectious diseases, women's health, and psychiatric conditions.
29 Sep
Eli Lilly CEO Dave Ricks announced at a conference in Milan that the company plans to pursue larger acquisitions to target underserved medical areas, including infectious diseases, women's health, and psychiatric conditions.
29 Sep
AstraZeneca announced a $2 billion investment in Summit Therapeutics on September 28, 2026.
28 Sep
Sterling Pharmaceutical Services LLC initiated a recall of over 500,000 Walgreens-branded eye-drop products on August 20, 2026, due to sterility concerns.
20 Aug (reported 04 Oct)
Sterling Pharmaceutical Services LLC initiated a recall of over 500,000 Walgreens-branded eye-drop products on August 20, 2026, due to sterility concerns.
20 Aug (reported 04 Oct)
Sterling Pharmaceutical Services LLC initiated a recall of over 500,000 Walgreens-branded eye-drop products on August 20, 2026, due to sterility concerns.
20 Aug (reported 04 Oct)
Costco reported $1.849 billion in membership fee income for the fourth quarter of fiscal 2026, a 7.3% increase year-over-year.
03 Oct
Costco reported $1.849 billion in membership fee income for the fourth quarter of fiscal 2026, a 7.3% increase year-over-year.
03 Oct
Costco reported $1.849 billion in membership fee income for the fourth quarter of fiscal 2026, a 7.3% increase year-over-year.
03 Oct
Costco reported $1.849 billion in membership fee income for the fourth quarter of fiscal 2026, a 7.3% increase year-over-year.
03 Oct
Federal authorities have charged store clerk Yahya Mohamed Mosleh and his son Islam Yahya Mosleh with possession with intent to distribute a controlled substance in Oxford, Mississippi.
24 Sep (reported 03 Oct)
Federal authorities have charged store clerk Yahya Mohamed Mosleh and his son Islam Yahya Mosleh with possession with intent to distribute a controlled substance in Oxford, Mississippi.
24 Sep (reported 03 Oct)
Federal authorities have charged store clerk Yahya Mohamed Mosleh and his son Islam Yahya Mosleh with possession with intent to distribute a controlled substance in Oxford, Mississippi.
24 Sep (reported 03 Oct)
Researchers at the University of Wisconsin-Madison, led by Barbara Bendlin and Federico Rey, identified that the gut-produced molecule imidazole propionate (ImP) is linked to an increased risk of Alzheimer's disease.
03 Oct
Kenney Blewett, a resident of Kyle, Texas, died by suicide after experiencing delays in receiving medication for his chronic obstructive pulmonary disease (COPD).
02 Jun (reported 02 Oct)
Kenney Blewett, a resident of Kyle, Texas, died by suicide after experiencing delays in receiving medication for his chronic obstructive pulmonary disease (COPD).
02 Jun (reported 02 Oct)
Researchers led by Jon Stefely at the Morgridge Institute for Research and the University of Wisconsin School of Medicine and Public Health have mapped the mitochondrial proteome of the pathogen Acanthamoeba castellanii.
02 Oct
Researchers led by Jon Stefely at the Morgridge Institute for Research and the University of Wisconsin School of Medicine and Public Health have mapped the mitochondrial proteome of the pathogen Acanthamoeba castellanii.
02 Oct
A study by the SCOP-GLP1 research team, involving participants from France, the United States, Brazil, and Mexico, found a correlation between GLP-1 medication use and increased risks of hair loss and nail detachment.
01 Oct (reported 02 Oct)
A study by the SCOP-GLP1 research team, involving participants from France, the United States, Brazil, and Mexico, found a correlation between GLP-1 medication use and increased risks of hair loss and nail detachment.
01 Oct (reported 02 Oct)
A study by the SCOP-GLP1 research team, involving participants from France, the United States, Brazil, and Mexico, found a correlation between GLP-1 medication use and increased risks of hair loss and nail detachment.
01 Oct (reported 02 Oct)
The American Medical Association released an analysis showing that the top four pharmacy benefit managers (PBMs) controlled 75% of the U.S. national market in 2024, an increase from 70% in 2022.
02 Oct
The American Medical Association released an analysis showing that the top four pharmacy benefit managers (PBMs) controlled 75% of the U.S. national market in 2024, an increase from 70% in 2022.
02 Oct
The American Medical Association released an analysis showing that the top four pharmacy benefit managers (PBMs) controlled 75% of the U.S. national market in 2024, an increase from 70% in 2022.
02 Oct
Former U.S. Border Patrol agent Cesar Daleo was arrested in 2017 for smuggling fentanyl precursors from China to Mexico via California.
02 Oct
Former U.S. Border Patrol agent Cesar Daleo was arrested in 2017 for smuggling fentanyl precursors from China to Mexico via California.
02 Oct
Former U.S. Border Patrol agent Cesar Daleo was arrested in 2017 for smuggling fentanyl precursors from China to Mexico via California.
02 Oct
Prime Therapeutics held its annual Specialty Summit in Washington, D.C., last month to discuss integrating medical and pharmacy benefits.
01 Oct
Prime Therapeutics held its annual Specialty Summit in Washington, D.C., last month to discuss integrating medical and pharmacy benefits.
01 Oct
Prime Therapeutics held its annual Specialty Summit in Washington, D.C., last month to discuss integrating medical and pharmacy benefits.
01 Oct
Prime Therapeutics held its annual Specialty Summit in Washington, D.C., last month to discuss integrating medical and pharmacy benefits.
01 Oct
Bank of America analyst Jason Gerberry raised the price target for Johnson & Johnson to $278 from $263, citing increased sales expectations for the new psoriasis drug Icotyde.
29 Sep (reported 01 Oct)
The UK Medicines and Healthcare products Regulatory Agency (MHRA) provides guidance on the New Active Substance Work Sharing Initiative (NASWSI) and the Biosimilar Work Sharing Initiative (BSWSI).
01 Oct
The UK Medicines and Healthcare products Regulatory Agency (MHRA) provides guidance on the New Active Substance Work Sharing Initiative (NASWSI) and the Biosimilar Work Sharing Initiative (BSWSI).
01 Oct
A 2026 survey by Pharmaceutical Strategies Group (PSG) of 250 benefits leaders shows overall satisfaction with pharmacy benefit managers (PBMs) remains stable at 7.2 out of 10.
30 Sep
A 2026 survey by Pharmaceutical Strategies Group (PSG) of 250 benefits leaders shows overall satisfaction with pharmacy benefit managers (PBMs) remains stable at 7.2 out of 10.
30 Sep
A 2026 survey by Pharmaceutical Strategies Group (PSG) of 250 benefits leaders shows overall satisfaction with pharmacy benefit managers (PBMs) remains stable at 7.2 out of 10.
30 Sep
A 2026 survey by Pharmaceutical Strategies Group (PSG) of 250 benefits leaders shows overall satisfaction with pharmacy benefit managers (PBMs) remains stable at 7.2 out of 10.
30 Sep
The Novo Nordisk Foundation has renewed its funding commitment to the Broad Institute on September 30, 2026.
30 Sep
On September 30, 2026, the U.S. Department of Health and Human Services (HHS) announced the launch of a five-year program called SURPASS in Washington.
30 Sep
Researchers at Boston Children’s Hospital and the Broad Institute, led by Vijay G. Sankaran, identified the BACH2-NRF2 axis as a novel regulatory pathway for fetal hemoglobin (HbF) activation.
30 Sep
Researchers at Boston Children’s Hospital and the Broad Institute, led by Vijay G. Sankaran, identified the BACH2-NRF2 axis as a novel regulatory pathway for fetal hemoglobin (HbF) activation.
30 Sep
Researchers at Boston Children’s Hospital and the Broad Institute, led by Vijay G. Sankaran, identified the BACH2-NRF2 axis as a novel regulatory pathway for fetal hemoglobin (HbF) activation.
30 Sep
A study analyzing medical records of over 300 million people in the US found that 1,133,953 adults without FDA-approved indications were prescribed GLP-1 drugs.
30 Sep
A study analyzing medical records of over 300 million people in the US found that 1,133,953 adults without FDA-approved indications were prescribed GLP-1 drugs.
30 Sep
A study analyzing medical records of over 300 million people in the US found that 1,133,953 adults without FDA-approved indications were prescribed GLP-1 drugs.
30 Sep
60 of 110 figures are listed; the rest were ranked lower by importance and multi-source corroboration and are not shown.
Publishers cited most often across the events on this page.
Choose the topics and sources that matter to you. Dailyn turns them into one concise digest.
Build my digest →Dailyn’s analysis engine screens the week’s reporting for relevance, deduplicates overlapping coverage into distinct dated events, and ranks those events by significance, source corroboration and recency. The highest-ranked events form the core of the weekly briefing.
Every line is a fact taken verbatim from a single dated article, and that article is linked in the same row. Nothing on the page is written or inferred beyond the article set.
The analysis engine extracts facts, entities and figures from the week’s reporting, and the editorial synthesis is generated from that event data. Published claims remain traceable to the underlying reporting.
A new briefing is issued for every ISO week, and the key-numbers section is refreshed with it. Each page states the exact window of dates it covers.
Dailyn’s analysis engine processes everything its monitored sources published this week: it deduplicates overlapping coverage, clusters reporting into distinct dated events, extracts the companies, deals and figures involved, and ranks the results by significance, corroboration and recency.
Everything Dailyn’s monitored sources published across the seven-day window.
The engine filters out off-topic and low-quality reporting.
Articles the engine tagged with this industry inside the window.
Sector articles that reported at least one figure inside the window.
The figures this page prints, each quoted exactly as its article reported it.
Events ranked by significance, corroboration and recency.
Every line on this page is a fact taken verbatim from a single dated article, with that article linked in the same row. Nothing on this page is written or inferred beyond the article set.
Duplicate reports of the same event are collapsed to one entry; the corroborating-source count says how many outlets carried it.
Dates are publication dates. Where an article states a different date for the event itself, that date is shown first and the publication date in brackets. A date the article gives for something still to come is shown as "due".
A figure is listed exactly as the article reported it. Figures are not converted, rebased, summed or compared across articles.
Every event stays linked to the reporting it was built from.
Pick the topics and sources that matter to you. Dailyn reads them every day and sends one concise digest.